Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

PCP Therapy: Aerosolized Pentamidine vs. TMP-SMX




 

AIDS Clinical Care (06/95) Vol. 7, No. 6, P. 51

As part of a randomized study of treatments for Pneumocystis carinii pneumonia (PCP), researchers assigned 367 patients to 21 days of treatment with either aerosolized pentamidine or trimethoprim-sulfamethoxazole (TMP-SMX). Each group also received placebos imitating the opposite treatment. After 35 days, mortality in the TMP-SMX group was higher, but not enough to be statistically significant. However, significantly more TMP-SMX recipients changed therapy because of toxicity, while significantly fewer did so because of slow clinical response. The greatest difference in response was among patients with an initial alveolar-arterial oxygen gradient greater than 30 mm Hg. After six months, there were fewer PCP recurrences with TMP-SMX, but the survival rates for the two drugs were almost identical. The researchers concluded that TMP-SMX appears to lead to more rapid improvements in oxygenation, more treatment successes, and fewer relapses than aerosolized pentamidine, but they are not sure why it did not also reduce mortality.



 


Copyright © 1995 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 7, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.